BiologicMD's lead development drug, PTH-CBD™, is focused on helping patients avoid the destructive effects of osteoporosis.  The initial results for the compound are very promising and have demonstrated five times the efficacy of available bisphosphonate treatments with fewer side effects in laboratory studies.   According to the National Osteoporosis Foundation, one in two women and one in four men will be diagnosed with osteoporosis in their lifetime.  The disease can have devastating consequences as it weakens bones and causes over 1.5 million osteoporosis patients to suffer a bone fracture every year.  Following a hip fracture, one in five patients will die within a year; 30% will need long term care.

Highlighting the potential for the medication, the company was selected in 2011 to receive a $2.3 million research award from the Department of Defense to further development of PTH-CBD™.   The funding is part of the U.S. Department of Defense Peer Reviewed Medical Research Program of the Office of the Congressionally Directed Medical Research Programs (CDMRP).  The program received more than 600 applications and fewer than 10 percent were recommended for funding.  Funds from the contract will be used to develop the manufacturing platform for PTH-CBD™.  The next step for the company is to complete the animal toxicology testing and then conduct a Phase I study in patients with osteoporosis according to FDA requirements. 

Reviews from the technical review committee highlight BiologicMD's expertise in drug development, stating that, "the investigators show a clear and concise understanding of bone biology, drug discovery and drug development … This proposal could have wide ranging consequences. Each stage of the proposed research is carefully crafted in a logical sequence." BiologicMD's President Paul Mlakar, Jr. added, "This approval process provides validation for the science behind a compound that could help millions by improving quality of life and saving lives."